Stocks Health care NEO
NASDAQ · Health careNeogenomics Inc (NEO)
Neogenomics Inc brought in $766.3M of revenue over the twelve months to June 30, 2026, up 11.2% from a year earlier. It posted a net loss of $51.9M. In fiscal 2025 capital spending exceeded operating cash flow by $21.8M. At June 30, 2026 it held $145.5M in cash against $374.2M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 28, 2026.
Key facts about Neogenomics Inc
- Net worth
- Neogenomics Inc has a market value (market cap) of $2.1B at the latest share price, and shareholders' equity of $785.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $727.3M (+10.1% year on year), with a net loss of $108M. Over the 12 months to June 30, 2026: revenue $766.3M, net loss $51.9M.
- Cash flow
- In fiscal 2025 operations brought in $5.2M of cash; after $27M of capital spending, free cash flow was -$21.8M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on July 28, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Neogenomics Inc's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Neogenomics Inc does
NeoGenomics operates diagnostic laboratories specializing in cancer genetics and molecular pathology testing. It provides clinical diagnostic, prognostic, and therapeutic tests to hospital networks, oncologists, pathology groups, and pharmaceutical researchers developing cancer treatments. Its shares trade on NASDAQ under the ticker NEO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $727.3M | -$108M | n/a | -$21.8M |
| 2024 | $660.6M | -$78.7M | n/a | -$34M |
| 2023 | $591.6M | -$88M | n/a | -$30.7M |
| 2022 | $509.7M | -$144.3M | n/a | -$96.9M |
| 2021 | $484.3M | -$8.3M | n/a | -$90.9M |
| 2020 | $444.4M | $4.2M | n/a | -$27.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where NEO ranks in Health care
Latest SEC filings
What Neogenomics Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 5, 2026Quarterly results8-KNeoGenomics announced a planned CEO succession and preliminary third quarter revenue of approximately $209 million.
- August 25, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 11, 2026
- July 30, 2026Passive stake changed SCHEDULE 13G/A
- July 30, 2026Passive stake (5% or more) SCHEDULE 13G
- July 28, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 11% to $201.7M versus the same quarter last year; net income of $2.2M versus a net loss of $45.1M.
- July 28, 2026
- July 22, 2026Investor disclosure 8-K/A
- July 20, 2026
Insider trades
What the people running Neogenomics Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $321.4K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 1, 2026 | Stone WarrenPres & Chief Operating Officer | Exercised options | 17,562 | - |
| October 1, 2026 | Stone WarrenPres & Chief Operating Officer | Shares withheld for tax | 6,911 | - |
| September 1, 2026 | Olivo Alicia CEVP, GC & Business Development | Shares withheld for tax | 2,692 | - |
| August 21, 2026 | Stone WarrenPres & Chief Operating Officer | Exercised options | 28,106 | - |
| August 21, 2026 | Stone WarrenPres & Chief Operating Officer | Shares withheld for tax | 11,060 | - |
| August 4, 2026 | Aunan Greg DChief Accounting Officer | Sold | 20,000 | $321.4K |
| June 15, 2026 | Tetrault Lynn A.Director | Soldpre-planned (10b5-1) | 5,307 | $58.9K |
| June 9, 2026 | Tetrault Lynn A.Director | Soldpre-planned (10b5-1) | 5,307 | $59.9K |
Who owns NEO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Mathew P. Arens13G, passive with 1 related filers | 8.37% | August 14, 2026 |
| First Trust Portfolios L.P.13G, passive with 2 related filers | 7.77% | July 30, 2026 |
| Greenhouse Funds LLLP13G, passive with 2 related filers | 7.1% | May 15, 2026 |
| Vanguard Portfolio Management13G, passive | 5.91% | April 29, 2026 |
| Vanguard Capital Management13G, passive | 5.09% | April 30, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 266 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 20,868,362 | +910,860 |
| First Light Asset Management, LLC | 12,279,523 | +2,549,545 |
| First Trust Advisors LP | 10,113,261 | +3,950,890 |
| Greenhouse Funds LLLP | 8,574,210 | -525,893 |
| Vanguard Portfolio Management LLC | 8,061,362 | +439,175 |
| Vanguard Capital Management LLC | 5,763,017 | +107,194 |
| State Street Corp | 5,363,784 | +243,946 |
| Nomura Asset Management International Inc. | 5,037,787 | +1,585,200 |
| Braidwell LP | 4,918,202 | -699,200 |
| Schroder Investment Management Group | 4,342,883 | +774,305 |
| Geode Capital Management, LLC | 3,428,123 | +197,051 |
| Millennium Management LLC | 3,079,542 | +856,785 |
| Loomis Sayles & Co L P | 2,537,717 | +592,329 |
| Driehaus Capital Management LLC | 2,508,845 | +787,095 |
| Bank of America Corp | 2,436,329 | -617,869 |
| Dimensional Fund Advisors LP | 2,399,411 | -274,924 |
| Arrowstreet Capital, Limited Partnership | 2,391,784 | new |
| American Capital Management Inc | 2,237,707 | -13,171 |
| D. E. Shaw & Co., Inc. | 2,194,758 | -1,969,425 |
| Samlyn Capital, LLC | 2,131,337 | -426,012 |
Insiders
13 insiders reported holding 1,036,737 shares in total, about $16.7M at the last price.
| Holder | Shares |
|---|---|
| Sherman Jeffrey ScottChief Financial Officer | 220,009 |
| Stone WarrenPres & Chief Operating Officer | 191,729 |
| Zook Anthony P.Chief Executive Officer, Director | 133,111 |
| Olivo Alicia CEVP, GC & Business Development | 90,875 |
| Tetrault Lynn A.Director | 86,115 |
| Kanovsky Stephen MDirector | 75,421 |
| Kelly Michael AaronDirector | 67,086 |
| Perez David BrianDirector | 56,967 |
| Gunn NeilDirector | 51,177 |
| Williams FeliciaDirector | 30,237 |
Questions about NEO
What does Neogenomics Inc do?
NeoGenomics operates diagnostic laboratories specializing in cancer genetics and molecular pathology testing. It provides clinical diagnostic, prognostic, and therapeutic tests to hospital networks, oncologists, pathology groups, and pharmaceutical researchers developing cancer treatments. Its shares trade on NASDAQ under the ticker NEO.
What is Neogenomics Inc's net worth?
Neogenomics Inc has a market value (market cap) of $2.1B at the latest share price, and shareholders' equity of $785.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Neogenomics Inc profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $51.9M on revenue of $766.3M.
How much revenue does Neogenomics Inc make?
Over the twelve months to June 30, 2026 Neogenomics Inc reported revenue of $766.3M. That is 11.2% more than a year earlier.
When did Neogenomics Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on July 28, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the quarterly results from October 5, 2026.
When is Neogenomics Inc's next earnings report?
Neogenomics Inc's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Theses that mention NEO
Similar companies
Compare NEO with
Follow NEO
Get an email when Neogenomics Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Neogenomics Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.